Andrea Loreto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrea Loreto has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Mootaz Mowfak Salman
Department of Physiology, Anatomy, and Genetics University of Oxford Oxford UK
1 shared publication - Philip Kitchen
Aston University
1 shared publication - Richard Wade-Martins
Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3QX, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford OX1 3QU, UK
1 shared publication - Roslyn M. Bill
Aston University Birmingham UK
1 shared publication - Zaid Mahdi Jaber Al-Obaidi
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Alkafeel, Najaf, Iraq
1 shared publication
Latest Publications
- Open Access
- 28 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (9) , 4688
Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases
Neurodegenerative diseases (NDs) including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease are incurable and affect millions of people worldwide. The development of treatments for this unmet clinical need is a major global research challenge. Computer-aided drug design (CADD) methods minimize the huge number of ligands that could be screened in biological assays, reducing the cost, time, and effort required to develop new drugs. In this review, we provide an introduction to CADD and examine the progress in applying CADD and other molecular docking studies to NDs. We provide an updated overview of potential therapeutic targets for various NDs and discuss some of the advantages and disadvantages of these tools.
- 28 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (9) , 4688
Open AccessAdvances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases
Neurodegenerative diseases (NDs) including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease are incurable and affect millions of people worldwide. The development of treatments for this unmet clinical need is a major global research challenge. Computer-aided drug design (CADD) methods minimize the huge number of ligands that could be screened in biological assays, reducing the cost, time, and effort required to develop new drugs. In this review, we provide an introduction to CADD and examine the progress in applying CADD and other molecular docking studies to NDs. We provide an updated overview of potential therapeutic targets for various NDs and discuss some of the advantages and disadvantages of these tools.